Royalty Report: Drugs, cardiac, Pharmaceuticals – Collection: 183006


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • cardiac
  • Pharmaceuticals
  • Disease
  • Enzymes
  • Diagnostic
  • Therapeutic
  • Cancer
  • recombinant proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 183006

License Grant
In February 2017, the parties agreed to exercise the option to co-invest in the Phase 3 development program of omecamtiv mecarbil.

In December 2006, the Parties entered into a collaboration and option agreement to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil,  The agreement granted an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration.  

In June 2013, the parties  executed an amendment to include Japan, resulting in a worldwide collaboration.   Under the Amendment, Parties conducted a Phase 1 pharmacokinetic study intended to support inclusion of Japan in a potential Phase 3 clinical development program and potential global registration dossier for omecamtiv mecarbil.

License Property
Omecamtiv mecarbil is a cardiac muscle myosin activator used to activate cardiac muscle contractility for potential applications in the treatment of heart failure.  This has a potential oral administration.
Field of Use
The Licensor / Collaborator is a late-stage biopharmaceutical company focused on the discovery and developments of first-in-class muscle activators as potential treatment for debilitating diseases in which muscle performance is compromised and/or declining.

IPSCIO Record ID: 240469

License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised.  This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.

Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.

IPSCIO Record ID: 28064

License Grant
University granted the Licensee an exclusive United States and worldwide license under the patent rights for cardiac disorders.
License Property
Patent shall mean U.S. patent application Serial No.  09/186,755  and PCT application PCT/US98/23878, each filed on 11/5/98; EPO application filed 08/0212000; all assigned to the University entitled Methods for Treatment of Disorders of Cardiac Contractility. Invention entitled Xanthine Oxidase Inhibitors as Calcium-Sensitizing Therapeutic Agents for Heart Failure.
Field of Use
The Licensed Field shall mean therapeutic, diagnostic and commercial use of xanthine oxidase inhibitors for cardiovascular and neuromuscular disease.

IPSCIO Record ID: 359108

License Grant
Canadian Licensor granted Licensee the sole, exclusive, irrevocable license to patented nanotechnologies for use with any drugs including cannabinoids,  to develop and optimize a proprietary nanoformulation of pharmaceutical cannabidiol, designed to avoid first-pass metabolism and improve bioavailability, for the treatment of heart failure.
License Property
Nanotechnologies are designed to improve solubilization, pharmacokinetics, and drug targeting of lipophilic drugs. Nanotechnologies is the use of matter on an atomic, molecular, and supramolecular scale for industrial purposes.

Cannabidiol is a non-psychoactive molecule with broad therapeutic potential in the treatment of chronic inflammatory disease including heart failure.

Field of Use
The license to patented nanotechnologies is for use with any drugs or classes of drugs currently used or developed in the future to diagnose or treat heart failure and/or any cardiovascular disease and/or cardiopulmonary disease and/or cardiac arrhythmias.

Field of use to treat cardiovascular disease, cardiopulmonary disease, and cardiac arrhythmias.

IPSCIO Record ID: 28000

License Grant
The Licensor granted an exclusive option to license its product candidate, TRV027. If Licensee exercises this option, the license agreement will become effective and Licensee will have an exclusive worldwide license to develop and commercialize TRV027 and specified related compounds.  The Licensor is about to conduct a Phase 2b trial of TRV027 in acute heart failure.
License Property
TRV027 is an intravenous drug for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy, and is currently being investigated in a Phase 2 clinical trial.

IPSCIO Record ID: 255044

License Grant
The Licensor and the Licensee entered into a new Strategic Drug Development Collaboration and License Agreement, to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.  The Licensee has sole and exclusive responsibility for all ex-U.S. commercialization efforts.
License Property
The Licensor is responsible for conducting and funding all discovery and preclinical development activities in accordance with an agreed upon discovery program plan for the IL12 program and any other discovery program the parties agree to conduct under Agreement.
Field of Use
To work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL12 protein.

Potential therapeutic mRNA medicines is directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.